Potential applications of MEG3 in cancer diagnosis and prognosis

Yuqing He _, Yanhong Luo, Biyu Liang, Lei Ye, Guangxing Lu and Weiming He

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:73282-73295. https://doi.org/10.18632/oncotarget.19931

Metrics: PDF 2716 views  |   HTML 3887 views  |   ?  


Yuqing He1,3,*, Yanhong Luo2,*, Biyu Liang2,*, Lei Ye2, Guangxing Lu2 and Weiming He2

1Institute of Medical Systems Biology, Guangdong Medical University, Dongguan 523808, China

2Department of Epidemiology and Medical Statistics, Guangdong Medical University, Dongguan 523808, China

3Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Guangdong Medical University, Dongguan 523808, China

*Authors contributed equally to this work

Correspondence to:

Yuqing He, email: [email protected]

Keywords: cancer, long noncoding RNAs, maternally expressed gene 3, apoptosis, MEG3

Received: June 01, 2017     Accepted: July 25, 2017     Published: August 04, 2017


LncRNAs are emerging as integral functional and regulatory components of normal biological activities and are now considered as critically involved in the development of different diseases including cancer. In this review, we summarized recent findings on maternally expressed gene 3 (MEG3), a noncoding lncRNA, locates in the imprinted DLK1–MEG3 locus on human chromosome 14q32.3 region. MEG3 is expressed in normal tissues but is either lost or decreased in many human tumors and tumor derived cell lines. Studies have demonstrated that MEG3 is associated with cancer initiation, progression, metastasis and chemo-resistance. MEG3 may affect the activities of TP53, MDM2, GDF15, RB1 and some other key cell cycle regulators. In addition, the level of MEG3 showed good correlation with cancer clinicopathological grade. In summary, MEGs is an RNA-based tumor suppressor and is involved in the etiology, progression, and chemosensitivity of cancers. The alteration of MEG3 levels in various cancers suggested the possibility of using MEG3 level for cancer diagnosis and prognosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19931